Evidence map›Paper›PMID 23144626›Full record

ArticlePLoS genetics2012

Mechanisms employed by Escherichia coli to prevent ribonucleotide incorporation into genomic DNA by Pol V.

John P McDonald, Alexandra Vaisman, Wojciech Kuban, Myron F Goodman, Roger Woodgate

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 37 citations in OpenAlex.

  1. Ribonucleotide errors, RNase HII, and ribonucleotide excision repair.Critical reviews in biochemistry and molecular biology · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. CroSMolecular microbiology · 2021
    Article
  6. Article
  7. Ribonucleotide incorporation into DNA during DNA replication and its consequences.Critical reviews in biochemistry and molecular biology · 2021
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Ribonucleotide discrimination by translesion synthesis DNA polymerases.Critical reviews in biochemistry and molecular biology · 2018
    Review
  14. Article
  15. Mutagenic cost of ribonucleotides in bacterial DNA.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

John P McDonaldLaboratory of Genomic Integrity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America.
Alexandra Vaisman
Wojciech Kuban
Myron F Goodman
Roger Woodgate
National Institutes of Health · USUniversity of Southern California · US

Funding

DNA Replication, Repair, and Mutagenesis In Eukaryotic And Prokaryotic CellsZIAHD001500 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI WOODGATE, ROGER · 2009 to 2025
$37.5M
ERROR CORRECTION IN DNA SYNTHESIS--A BIOCHEMICAL STUDYR37GM021422 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GOODMAN, MYRON · 2000 to 2009
$3.5M
ERROR CORRECTION IN DNA SYNTHESIS: A BIOCHEMICAL STUDYR01GM021422 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GOODMAN, MYRON · 1985 to 2014
$1.6M
Intramural NIH HHSNIGMS NIH HHS GM21422NIGMS NIH HHS R01 GM021422NIGMS NIH HHS R37 GM021422PHS HHS ESO12259
6 · The paper itself

Abstract

Escherichia coli pol V (UmuD'(2)C), the main translesion DNA polymerase, ensures continued nascent strand extension when the cellular replicase is blocked by unrepaired DNA lesions. Pol V is characterized by low sugar selectivity, which can be further reduced by a Y11A "steric-gate" substitution in UmuC that enables pol V to preferentially incorporate rNTPs over dNTPs in vitro. Despite efficient error-prone translesion synthesis catalyzed by UmuC_Y11A in vitro, strains expressing umuC_Y11A exhibit low UV mutability and UV resistance. Here, we show that these phenotypes result from the concomitant dual actions of Ribonuclease HII (RNase HII) initiating removal of rNMPs from the nascent DNA strand and nucleotide excision repair (NER) removing UV lesions from the parental strand. In the absence of either repair pathway, UV resistance and mutagenesis conferred by umuC_Y11A is significantly enhanced, suggesting that the combined actions of RNase HII and NER lead to double-strand breaks that result in reduced cell viability. We present evidence that the Y11A-specific UV phenotype is tempered by pol IV in vivo. At physiological ratios of the two polymerases, pol IV inhibits pol V-catalyzed translesion synthesis (TLS) past UV lesions and significantly reduces the number of Y11A-incorporated rNTPs by limiting the length of the pol V-dependent TLS tract generated during lesion bypass in vitro. In a recA730 lexA(Def) ΔumuDC ΔdinB strain, plasmid-encoded wild-type pol V promotes high levels of spontaneous mutagenesis. However, umuC_Y11A-dependent spontaneous mutagenesis is only ~7% of that observed with wild-type pol V, but increases to ~39% of wild-type levels in an isogenic ΔrnhB strain and ~72% of wild-type levels in a ΔrnhA ΔrnhB double mutant. Our observations suggest that errant ribonucleotides incorporated by pol V can be tolerated in the E. coli genome, but at the cost of higher levels of cellular mutagenesis.

Indexed as

Escherichia coliRibonucleotidesDNA, BacterialDNA-Directed DNA PolymeraseDNA RepairEscherichia coli ProteinsGenome, BacterialMutagenesisRibonuclease HUltraviolet RaysDNA, BacterialDNA-Directed DNA PolymeraseEscherichia coli ProteinsRibonuclease Hribonuclease HIIRibonucleotidesUmuC protein, E coliUmuD protein, E coli

Identifiers

PMID23144626
PMCPMC3493448
OpenAlexW1979994225

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.